Companies · Other Health Care

Kypha Inc.

SAINT LOUIS · Other Health Care

Diligence memoA one-page analyst read on Kypha Inc. — recommendation, valuation, rhythm, risks.
$15.2M
Total raised · real
8
Rounds
5.4×
Latest step-up
Top 20%
Sector rank · raised
Series A
Latest stage · inferred · Fri Apr 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Kypha Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.50× the median modeled value of Series A Other Health Care companies in 2022–2024 (196 peers) — value vs value, same stage and era.
Dormant
  • Last raise 4.2 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Kypha Inc. is one of 5376 Other Health Care companies tracked from SAINT LOUIS. By capital raised it ranks in the upper tier (ahead of 81% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
13
Investors (latest)
2022-04-08
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MPre-Seed · 2011-11-22 Raised $206K (real) Modeled valuation $6.3M (est)Pre-Seed2011Pre-Seed · 2012-06-25 Raised $200K (real) Modeled valuation $6.2M (est)Pre-Seed2012Pre-Seed · 2013-03-01 Raised $750K (real) Modeled valuation $23M (est)Pre-Seed2013Pre-Seed · 2013-12-30 Raised $398K (real) Modeled valuation $12M (est)Pre-Seed2013Seed · 2015-02-20 Raised $2.1M (real) Modeled valuation $52M (est)Seed2015Series A · 2018-04-30 Raised $5.5M (real) Modeled valuation $110M (est)Series A2018Seed · 2018-04-30 Raised $1.6M (real) Modeled valuation $39M (est)Seed2018Series A · 2018-06-19 Raised $950K (real) Modeled valuation $19M (est)Series A2018Series A · 2022-04-08 Raised $5.2M (real) Modeled valuation $55M (est)Series A2022+$200K+$750K+$398K+$2.1M+$5.5M+$1.6M+$950K+$5.2MCumulative $17M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$206K · 2011
Pre-Seed extension$200K · 2012
Pre-Seed extension$750K · 2013
Pre-Seed extension$398K · 2013
Seed$2.1M · 2015
Series A$5.5M · 2018
Bridge · Series A-stage$1.6M · 2018smaller follow-on
Series A extension$950K · 2018
Series A extension$5.2M · 2022

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$55.1M
Base estimate est.
$6.6M
Conservative case
$199.3M
Upside case
$23.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $6.3M · 2011-11-222011Pre-Seed · modeled $6.2M · 2012-06-25Pre-Seed · modeled $23.1M · 2013-03-01Pre-Seed · modeled $12.3M · 2013-12-30Seed · modeled $52.1M · 2015-02-20Series A · modeled $110.1M · 2018-04-30Seed · modeled $38.5M · 2018-04-30Series A · modeled $19.2M · 2018-06-19Series A · modeled $55.1M · 2022-04-082022
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
52%
Survival probability
28% low · 71% high
1.43×/yr
Annual markup
1.80×/yr upside case
4.2 yr
Elapsed time used
4.2 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
16 mo
Avg between rounds
$1.5M/yr
Capital velocity
14.6 yr
On record since
2011
First round
9
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 6.3× above median
This company$15.2M
Sector median$2.4M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.9× of median
This company$5.2M
Sector median$5.6M
Modeled value — vs sector median (estimate, all stages) 2.5× above median
This company$55.1M
Sector median$22.1M

Raised more than 81% of sector peers (real $). Modeled value above 68% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #48 of 196.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)CareHarmony, Inc. · Series A Raised $17.4M · modeled $145.1M (est)Dragonfly Endoscopy Inc. · Series A Raised $12.7M · modeled $141.8M (est)NuvoAir Holdings, Inc. · Series A Raised $10.7M · modeled $124.9M (est)Post Acute Recovery, Inc. · Series A Raised $14.5M · modeled $122.9M (est)Micro Interventional Devices, Inc. · Series A Raised $14.0M · modeled $118.9M (est)Etiometry Inc. · Series A Raised $15.6M · modeled $114.6M (est)SafKan, Inc. · Series A Raised $13.0M · modeled $108.4M (est)BehaVR Holdings, Inc. · Series A Raised $12.1M · modeled $102.0M (est)Outliers Inc. · Series A Raised $13.6M · modeled $101.6M (est)RevMedica, Inc. · Series A Raised $14.2M · modeled $101.1M (est)Innovoyce LLC · Series A Raised $9.9M · modeled $97.5M (est)Prixz, Inc. · Series A Raised $9.2M · modeled $97.3M (est)Kypha Inc. (this company) Raised $15.2M · modeled $55.1M (est)Kypha Inc.
CompanyStageRaised · realValue · estvs peer med.
CareHarmony, Inc.Series A$17.4M$145.1M3.96×
Dragonfly Endoscopy Inc.Series A$12.7M$141.8M3.87×
NuvoAir Holdings, Inc.Series A$10.7M$124.9M3.41×
Post Acute Recovery, Inc.Series A$14.5M$122.9M3.35×
Micro Interventional Devices, Inc.Series A$14.0M$118.9M3.25×
Etiometry Inc.Series A$15.6M$114.6M3.13×
SafKan, Inc.Series A$13.0M$108.4M2.96×
BehaVR Holdings, Inc.Series A$12.1M$102.0M2.78×
Outliers Inc.Series A$13.6M$101.6M2.77×
RevMedica, Inc.Series A$14.2M$101.1M2.76×
Innovoyce LLCSeries A$9.9M$97.5M2.66×
Prixz, Inc.Series A$9.2M$97.3M2.66×
Kypha Inc. this companySeries A$15.2M$55.1M1.50×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$206K2011-11-22$1.1M$6.3M85%
Pre-Seed$200K2012-06-25$1.1M$6.2M85%
Pre-Seed$750K2013-03-01$4.2M$23.1M85%
Pre-Seed$398K2013-12-30$2.2M$12.3M85%
Seed$2.1M2015-02-20$10.5M$52.1M85%
Series A$5.5M2018-04-30$24.8M$110.1M90%
Seed$1.6M2018-04-30$7.8M$38.5M90%
Series A$950K2018-06-19$4.3M$19.2M90%
Series A$5.2M2022-04-08$23.4M$55.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$206K2011-11-22
    • First recorded raise — entered as Pre-Seed.
    • 10 investors on this round.
  2. Pre-Seed$200K2012-06-25
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  3. Pre-Seed$750K2013-03-01
    • Raised 8 mo later, in step with the ~14 mo sector norm.
    • Round 3.8× larger than the prior — scaling up.
    • 3 investors on this round.
  4. Pre-Seed$398K2013-12-30
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round 1.9× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
    • 1 investor on this round.
  5. Seed$2.1M2015-02-20
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 5.3× larger than the prior — scaling up.
    • 3 investors on this round.
  6. Series A$5.5M2018-04-30
    • Raised again after 38 mo — slower than the ~14 mo sector norm.
    • Round 2.6× larger than the prior — scaling up.
    • 13 investors on this round.
  7. Seed$1.6M2018-04-30
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.5× smaller than the prior — bridge or down round.
    • 13 investors on this round.
  8. Series A$950K2018-06-19
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 1.6× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  9. Series A$5.2M2022-04-08
    • Raised again after 46 mo — slower than the ~14 mo sector norm.
    • Round 5.4× larger than the prior — scaling up.
    • 13 investors on this round.
Intelligence
2023 ~Q3
Modeled next raise · ~16mo cadence
$15.4M
Modeled next size est.range $10.0M$24.7M
5.4×
Last step-up
$1.5M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
David Smoller5 other2013-12
Jonathan Sackier3 other2018-04
James Merselis2 other2018-04
David D. Smoller1 other2015-02
Dennert Ware1 other2022-04
Paul Olson1 other2013-12
Peter Reinecke1 other2013-12
Sultan Meghji1 other2013-12
Chad D. Stiening2015-02
Chad M. Stiening2011-11
Chad Stiening2013-12
David K. Smoller2013-03
Gerhard Bette2022-04
James D. Marselis2015-02
Jonathan D. Sackier2015-02
Nick A. Staten2013-12
Nick Scott Staten2015-02
Paul K. Olson2011-11
Peter A. Takes2013-12
Peter D. Reinecke2015-02
Peter K. Reinecke2013-03
R. Charles Moyer2011-11
T. Scott Glover2015-02
T. Vernon Foster2011-11
Registry & provenance

Kypha Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1539371
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
HemoSonics, LLCOther Health CareSeries A$24.9M$302.7Mnetwork1 shared operator · same sector · same stage
Celltrio, Inc.Other Health CareSeries A$15.0M$50.8Msame sector · same stage
Consensus Orthopedics IncOther Health CareSeries A$14.9M$41.9Msame sector · same stage
Elenza, IncOther Health CareSeries A$14.6M$67.2Msame sector · same stage
H-Cyte, Inc.Other Health CareSeries A$14.6M$58.1Msame sector · same stage
On Belay Holdings, Inc.Other Health CareSeries A$15.9M$42.3Msame sector · same stage
Vomaris Innovations, Inc.Other Health CareSeries A$16.2M$60.5Msame sector · same stage
Learn to Live, Inc.Other Health CareSeries A$14.3M$63.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
MedPharm Holdings, LLCOther Health CareSeries A$100.9M86%
SmartPhage, Inc.Other Health CarePre-Seed$16.8M83%
Kures Inc.Other Health CareSeries A$85.6M83%
Sofia Holdings LtdOther Health CareSeries B$333.0M81%
Rimidi, Inc.Other Health CareSeries A$1.4M81%
Akumin Inc.Other Health CareSeed$67.6M81%
Aetas Co LLCOther Health CarePre-Seed$30.8M81%
Ostial CorpOther Health CareSeries A$71.6M81%
Frequently asked
How much funding has Kypha Inc. raised?
Kypha Inc. has raised approximately $15.2M in disclosed capital across 8 recorded financing rounds, aggregated from public filings.
What is Kypha Inc.'s estimated valuation?
Provath's modeled valuation for Kypha Inc. is approximately $55.1M (modeled range $6.6M–$199.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Kypha Inc. at?
Kypha Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Fri Apr 08.
What does Kypha Inc. do and where is it based?
Kypha Inc. operates in the Other Health Care sector, based in SAINT LOUIS.
Explore related

See where Kypha Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Kypha Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.